Lukas Scheibler - Apr 4, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF INNOVATION OFFICER
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol: APLS
Transactions as of: Apr 4, 2022
Transactions value $: -$151,059
Form type: 4
Date filed: 4/5/2022, 04:08 PM
Previous filing: Apr 4, 2022
Next filing: Apr 6, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$48.5K	+3.5K	+6.71%	$13.85	55.7K	Apr 4, 2022	Direct	F1
transaction	APLS	Common Stock	Sale	-$45.7K	-818	-1.47%	$55.84	54.9K	Apr 4, 2022	Direct	F1, F2
transaction	APLS	Common Stock	Sale	-$81.7K	-1.44K	-2.62%	$56.86	53.5K	Apr 4, 2022	Direct	F1, F3
transaction	APLS	Common Stock	Sale	-$72.2K	-1.25K	-2.34%	$57.81	52.2K	Apr 4, 2022	Direct	F1, F4

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-3.5K	-6.55%	$0.00	50K	Apr 4, 2022	Common Stock	3.5K	$13.85	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from 10B5-1 trading plan.
F2	The sale price range within $1.00. Max. $55.21 - Min. $56.13
F3	The sale price range within $1.00. Max. $56.34 - Min. $57.22
F4	The sale price range within $1.00. Max. $57.37 - Min. $58.29.
F5	This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.